Tectonic Therapeutic, Inc. (TECX)

NGM – Цена в реальном времени. Валюта: USD

27.96

+0.44 (1.60%)

При закрытии: May 12, 2026, 4:00 PM EDT

07.05.2026

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the first quarter ended March 31, 2026, and provided an overview of recent business highlights.

23.04.2026

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026.

16.04.2026

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF, a large underserved market. TX45's engineered Fc-relaxin fusion overcomes prior failures by extending half-life, enabling durable hemodynamic improvements in the CpcPH subgroup per robust phase 1b data. With a $253.8M cash balance, TECX is funded for phase 2; positive topline data in 2026 could unlock a $0.6B–$1.8B U.S. peak sales opportunity.

06.03.2026

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

26.02.2026

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent business highlights.

23.02.2026

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board.

11.02.2026

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET.

Видео

No Data

There is no data to display

Пресс-релизы

07.05.2026

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

23.04.2026

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

26.02.2026

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

23.02.2026

Tectonic Therapeutic, Inc. (TECX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Видео

No Data

Пресс-релизы

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Видео

No Data

Пресс-релизы

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Search stocks

Tectonic Therapeutic, Inc. (TECX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Tectonic Therapeutic, Inc. (TECX)

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Видео

No Data

Пресс-релизы

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2

Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026

Видео

No Data

Пресс-релизы

Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors

Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board